This is a working overview of modified GRF(1-29), written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-30. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
protoplasm The biological contents enclosed within a membrane-bound space, variously referring to the cytoplasm, or the cytoplasm and nucleoplasm considered collectively, and sometimes exclusive of vacuoles.
Hyperinsulinemic hypoglycemia describes the condition and effects of low blood glucose caused by excessive insulin. Hypoglycemia due to excess insulin is the most common type of serious hypoglycemia. It can be due to endogenous or injected insulin.
In contrast, Slavic settlements in southern Ukraine started to appear relatively early during Cuman rule, with the earliest, such as Oleshia, dating back to the 11th century. Early "Proto-Cossack" groups are generally reported to have come into existence within what is now Ukraine prior to the 13th century as the influence of Cumans grew weaker, although some have ascribed their origins to as early as the mid-8th century. Some historians suggest that the Cossack people were descended from East Slavs, Turks, Tatars, Circassians and others who settled or passed through the vast regions. There are archeological indications, according to Turkologists, that Cossacks are descendants of the native Cumans of Ukraine, who had lived there long before the Mongol invasion. Other theories expand upon that assertion to suggest that the first Cossacks were of Turkic origin. For example, according to Serhii Plokhy, the first Cossacks were of Turkic rather than Slavic stock. Christoph Baumer states that Cossack predecessors from the thirteenth century onward were mainly of Turkic stock, but from the sixteenth century the Cossacks were increasingly joined by Slavs such as Russians and Poles, Baltic Lithuanians and people from today's Ukraine, thus becoming a Slav-Tatar ethnic hybrid. The theory is also reflected in the Constitution of Pylyp Orlyk of 1710 and the Hrabianka Chronicle, which claims Khazar origins for the Cossacks. The Khazar origin myth became popular during the rule of Ivan Mazepa, a reaction against the Polish myth of Sarmatism.
Furthermore, it has been observed in many retrospective longitudinal studies that corticosteroid treatment does not seem to significantly prolong survival of the native liver or transplant-free survival.
Sources: en.wikipedia.org
=== Regulation of reactivity of monomer === To modulate the reactivity between monomer and growing polymeric chain is another approach to enhance sequence control. The rationale for this method is that monomer has to be activated with first catalyst at beginning as a dormant species, which could then participate into polymerization as the second catalyst is introduced. A real example is utilization of HI as first catalyst and ZnI2 as second catalyst to achieve sequence-controlled polymerization of vinyl ethers and styrene derivatives.
Protonitazene is a benzimidazole derivative with potent opioid effects which has been sold over the internet as a designer drug since 2019, and has been identified in various European countries, as well as Canada, the US and Australia. It has been linked to numerous cases of drug overdose, and is a Schedule I drug in the US. It was developed by a Swiss pharmaceutical company in the 1950s as an alternative to morphine, but was never adopted due to severe side effects.
In September 2024, the US FDA approved pembrolizumab with pemetrexed and platinum chemotherapy as first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma. In March 2025, the US FDA granted traditional approval to pembrolizumab with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (CPS ≥1). Pembrolizumab previously received accelerated approval for this indication in May 2021. Efficacy was evaluated in KEYNOTE-811 (NCT03615326), a multicenter, randomized, double-blind, placebo-controlled trial enrolling 698 participants with HER2-positive advanced gastric or GEJ adenocarcinoma not previously treated with systemic therapy for metastatic disease. Among the 698 participants, 594 (85%) had tumors expressing PD-L1 with a CPS ≥1 using the PD-L1 IHC 22C3 pharmDx kit. Participants were randomized (1:1) to pembrolizumab 200 mg or placebo, in combination with trastuzumab and either fluorouracil plus cisplatin or capecitabine plus oxaliplatin. In June 2025, the US FDA approved neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck squamous cell carcinoma.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
Cool, dark, and dry conditions are standard, with storage at minus twenty degrees Celsius or below. Desiccant and sealed vials limit moisture uptake. Repeated warming and cooling of the container is generally avoided.